EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib

Robert Harrington, Patricia Harkins iD, Richard Conway iD

Journal of Clinical Medicine · 23.10.2023 · 12 (20) · 6690

DOI: 10.3390/jcm12206690 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.10.2023. Verfasst von Robert Harrington und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, St. James's Hospital, James Street, Dublin 8, D08 NHY1 Dublin, Ireland. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Janus kinase inhibitors (JAKis) are the most recent new drug class to arrive to the market for rheumatoid arthritis (RA) treatment. While they have proven to be a very effective treatment option, there remains significant concern regarding the risk of cardiovascular events, thrombosis and malignancy, particularly given the findings of the post-marketing ORAL Surveillance study and FDA black box warnings. This article reviews the key findings of the most impactful cohort of studies and registry data since ORAL Surveillance. It also evaluates the role of JAKis in practice and offers guidance on risk stratifying patients and determining their suitability for a JAKi.

Schlagwörter

Stichwörter der Autor:innen

JAK inhibitorJAKiJanus kinase inhibitiorMACEORAL surveillanceRAVTEefficacymalignancyrheumatoid arthritissafetythromboembolism

Autor:innen und Institutionen

  • Department of Rheumatology, St. James's Hospital, James Street, Dublin 8, D08 NHY1 Dublin, Ireland.

ORCID-Profile: Patricia Harkins, Richard Conway

Zitieren

APA

Harrington, R., Harkins, P., & Conway, R. (2023). Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib. Journal of Clinical Medicine, 12(20), 6690. https://doi.org/10.3390/jcm12206690

Vancouver

Harrington R, Harkins P, Conway R. Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib. Journal of Clinical Medicine. 2023;12(20):6690. doi:10.3390/jcm12206690

BibTeX
@article{Harrington2023,
  author = {Harrington, Robert and Harkins, Patricia and Conway, Richard},
  title = {Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {20},
  pages = {6690},
  doi = {10.3390/jcm12206690}
}
Kostenlos starten →